These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 29172034)

  • 1. Development of mannose functionalized dendrimeric nanoparticles for targeted delivery to macrophages: use of this platform to modulate atherosclerosis.
    He H; Yuan Q; Bie J; Wallace RL; Yannie PJ; Wang J; Lancina MG; Zolotarskaya OY; Korzun W; Yang H; Ghosh S
    Transl Res; 2018 Mar; 193():13-30. PubMed ID: 29172034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoparticle-based "Two-pronged" approach to regress atherosclerosis by simultaneous modulation of cholesterol influx and efflux.
    He H; Wang J; Yannie PJ; Korzun WJ; Yang H; Ghosh S
    Biomaterials; 2020 Nov; 260():120333. PubMed ID: 32853832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of liver X receptor decreases atherosclerosis in Ldlr⁻/⁻ mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells.
    Kappus MS; Murphy AJ; Abramowicz S; Ntonga V; Welch CL; Tall AR; Westerterp M
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):279-84. PubMed ID: 24311381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoparticles containing a liver X receptor agonist inhibit inflammation and atherosclerosis.
    Zhang XQ; Even-Or O; Xu X; van Rosmalen M; Lim L; Gadde S; Farokhzad OC; Fisher EA
    Adv Healthc Mater; 2015 Jan; 4(2):228-36. PubMed ID: 25156796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Nanotherapeutics Encapsulating Liver X Receptor Agonist GW3965 Enhance Antiatherogenic Effects without Adverse Effects on Hepatic Lipid Metabolism in Ldlr
    Yu M; Amengual J; Menon A; Kamaly N; Zhou F; Xu X; Saw PE; Lee SJ; Si K; Ortega CA; Choi WI; Lee IH; Bdour Y; Shi J; Mahmoudi M; Jon S; Fisher EA; Farokhzad OC
    Adv Healthc Mater; 2017 Oct; 6(20):. PubMed ID: 28730752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of macrophage overexpression of murine liver X receptor-alpha (LXR-alpha) on atherosclerosis in LDL-receptor deficient mice.
    Teupser D; Kretzschmar D; Tennert C; Burkhardt R; Wilfert W; Fengler D; Naumann R; Sippel AE; Thiery J
    Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):2009-15. PubMed ID: 18787185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly(ADP-ribose) Polymerase 1 Represses Liver X Receptor-mediated ABCA1 Expression and Cholesterol Efflux in Macrophages.
    Shrestha E; Hussein MA; Savas JN; Ouimet M; Barrett TJ; Leone S; Yates JR; Moore KJ; Fisher EA; Garabedian MJ
    J Biol Chem; 2016 May; 291(21):11172-84. PubMed ID: 27026705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloid LXR (Liver X Receptor) Deficiency Induces Inflammatory Gene Expression in Foamy Macrophages and Accelerates Atherosclerosis.
    Endo-Umeda K; Kim E; Thomas DG; Liu W; Dou H; Yalcinkaya M; Abramowicz S; Xiao T; Antonson P; Gustafsson JÅ; Makishima M; Reilly MP; Wang N; Tall AR
    Arterioscler Thromb Vasc Biol; 2022 Jun; 42(6):719-731. PubMed ID: 35477277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic High-Density Lipoprotein-Mediated Targeted Delivery of Liver X Receptors Agonist Promotes Atherosclerosis Regression.
    Guo Y; Yuan W; Yu B; Kuai R; Hu W; Morin EE; Garcia-Barrio MT; Zhang J; Moon JJ; Schwendeman A; Eugene Chen Y
    EBioMedicine; 2018 Feb; 28():225-233. PubMed ID: 29361501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macrophage Lxrα reduces atherosclerosis in Ldlr
    Yin Y; Zeng S; Li Y; Wu Z; Huang D; Gao P
    Biochem Biophys Res Commun; 2020 Aug; 529(3):540-547. PubMed ID: 32736671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Andrographolide Inhibits Oxidized LDL-Induced Cholesterol Accumulation and Foam Cell Formation in Macrophages.
    Lin HC; Lii CK; Chen HC; Lin AH; Yang YC; Chen HW
    Am J Chin Med; 2018; 46(1):87-106. PubMed ID: 29298513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LXR Agonist T0901317's Hepatic Impact Overrules Its Atheroprotective Action in Macrophages, Driving Early Atherogenesis in Chow-Diet-Fed Male Apolipoprotein E Knockout Mice.
    Hoekstra M; de Jong LM; van der Geest R; de Leeuw LR; Krisnamurthi R; Geerling JJ; Van Eck M
    Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of notch enhances the anti-atherosclerotic effects of LXR agonists while reducing fatty liver development in ApoE-deficient mice.
    Hao Y; Wang X; Zhang F; Wang M; Wang Y; Wang H; Du Y; Wang T; Fu F; Gao Z; Zhang L
    Toxicol Appl Pharmacol; 2020 Nov; 406():115211. PubMed ID: 32853627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver X receptor-mediated induction of cholesteryl ester transfer protein expression is selectively impaired in inflammatory macrophages.
    Lakomy D; Rébé C; Sberna AL; Masson D; Gautier T; Chevriaux A; Raveneau M; Ogier N; Nguyen AT; Gambert P; Grober J; Bonnotte B; Solary E; Lagrost L
    Arterioscler Thromb Vasc Biol; 2009 Nov; 29(11):1923-9. PubMed ID: 19679828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver X receptor agonist methyl-3β-hydroxy-5α,6α-epoxycholanate attenuates atherosclerosis in apolipoprotein E knockout mice without increasing plasma triglyceride.
    Yan W; Zhang T; Cheng J; Zhou X; Qu X; Hu H
    Pharmacology; 2010; 86(5-6):306-12. PubMed ID: 21071998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel small molecule liver X receptor transcriptional regulator, nagilactone B, suppresses atherosclerosis in apoE-deficient mice.
    Gui Y; Yao S; Yan H; Hu L; Yu C; Gao F; Xi C; Li H; Ye Y; Wang Y
    Cardiovasc Res; 2016 Oct; 112(1):502-14. PubMed ID: 27460841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic deletion of low density lipoprotein receptor impairs sterol-induced mouse macrophage ABCA1 expression. A new SREBP1-dependent mechanism.
    Zhou X; He W; Huang Z; Gotto AM; Hajjar DP; Han J
    J Biol Chem; 2008 Jan; 283(4):2129-38. PubMed ID: 18029360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mindin deficiency in macrophages protects against foam cell formation and atherosclerosis by targeting LXR-β.
    Zhang C; Qin JJ; Gong FH; Tong JJ; Cheng WL; Wang H; Zhang Y; Zhu X; She ZG; Xia H; Zhu LH
    Clin Sci (Lond); 2018 Jun; 132(11):1199-1213. PubMed ID: 29695588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of MEK1/2 inhibitor and LXR ligand synergistically inhibit atherosclerosis in LDLR deficient mice.
    Yang J; Liu L; Yang X; Duan Y; Zeng P; Yang S; Ma C; Li X; Han J; Chen Y
    Biochem Biophys Res Commun; 2020 Feb; 522(2):512-517. PubMed ID: 31784089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced synthesis of the oxysterol 24(S),25-epoxycholesterol in macrophages by inhibitors of 2,3-oxidosqualene:lanosterol cyclase: a novel mechanism for the attenuation of foam cell formation.
    Rowe AH; Argmann CA; Edwards JY; Sawyez CG; Morand OH; Hegele RA; Huff MW
    Circ Res; 2003 Oct; 93(8):717-25. PubMed ID: 14512442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.